All In Biotech

NDA 205776 · Medexus

Rasuvo

Methotrexate · Subcutaneous

Last checked: Nov 19, 2026Latest source record: Mar 11, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jul 10, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,087

570 Phase 3, 211 recruiting

FAERS reports

419,222

315,734 serious, 34,424 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY AND DEATH Rasuvo should be used only by physicians whose knowledge and experience include the use of antimetabolite therapy. Because of the possibility of serious toxic reactions (which can be fatal), Rasuvo should be used only in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician's care throughout therapy [see Warnings and Precautions (5.1) ]. 1. Methotrexate can cause embryo-fetal toxicity, including fetal...

What it is approved for

From the label in effect Dec 15, 2025.

Rasuvo is a folate analog metabolic inhibitor indicated for the: Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy ( 1.1 ) Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy ( 1.2 ) Limitation of Use Rasuvo is not indicated for the treatment of neoplastic diseases ( 1.3 ). 1.1 Rheumatoid Arthritis including Polyarticular Juvenile Idiopathic Arthritis Rasuvo is indicated in the management of selected adults with severe, active rheumatoid arthritis (RA) (ACR criteria), or children with active polyarticular juvenile idiopathic arthritis (pJIA), who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). 1.2 Psoriasis Rasuvo is indicated in adults for the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis "flare" is not due to an undiagnosed concomitant disease affecting immune responses. 1.3 Limitation of Use Rasuvo is not indicated for the treatment of neoplastic diseases.

Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in rheumatoid arthritis is unknown; it may...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 10, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
10 products under this application
  • RASUVO · METHOTREXATE 27.5MG/0.55ML (27.5MG/0.55ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, SUBCUTANEOUS · Discontinued
  • RASUVO · METHOTREXATE 22.5MG/0.45ML (22.5MG/0.45ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 17.5MG/0.35ML (17.5MG/0.35ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 12.5MG/0.25ML (12.5MG/0.25ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 7.5MG/0.15ML (7.5MG/0.15ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 25MG/0.5ML (25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 20MG/0.4ML (20MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 15MG/0.30ML (15MG/0.30ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 30MG/0.6ML (30MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • RASUVO · METHOTREXATE 10MG/0.20ML (10MG/0.20ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,087 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective76,167
  • rheumatoid arthritis38,742
  • arthralgia37,040
  • pain36,175
  • off label use35,398
  • fatigue29,748
  • nausea24,560
  • joint swelling22,754
  • headache21,380
  • rash20,425
  • condition aggravated20,328
  • drug intolerance20,034

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,129
20055,083
20064,969
20077,782
20088,995
20099,160
20109,678
201110,610
201214,953
201316,975
201416,960
201520,367
201621,911
201722,794
201832,709
201932,625
202039,943
202126,674
202229,451
202327,028
202423,322
202520,237
202611,858

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rasuvo (Methotrexate/PF)

2024 spending

$22.5M

Beneficiaries

5,475

31,894 claims

Per beneficiary

$4,107

$367.06 per unit

View as table
YearSpending
2020$14,514,049
2021$15,516,396
2022$17,615,129
2023$20,891,563
2024$22,487,936

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Medexus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.